Keyword: Charles Grassley
Complacent about drug-pricing action in Congress? Despite the chaos of impeachment and elections, lawmakers are still taking drug pricing seriously.
The Senate Finance Committee chair is investigating Novartis' handling of manipulated Zolgensma data and its decision to delay telling the FDA.
If Trump wants to allow foreign imports, FDA inspectors need to show up unannounced at foreign plants, especially in India and China, senator says.
A slew of Republican senators threatened to side with manufacturers against legislation supported by their own committee chairman and president.
D.C. is buzzing with flashy proposals to confront drug prices. All of them face big hurdles—including pharma’s lobbying prowess.
After Mylan's high-profile EpiPen misclassification, lawmakers have passed a bill cracking down on Medicaid misrepresentations that cost taxpayers.
Sen. Charles Grassley, R-Iowa, vowed to haul pharma CEOs into Senate drug-pricing hearings. Now, several have heeded the call.
Lawmakers on both sides of the aisle refuse to let go of the proposal to force drug pricing into consumer advertising, but they're not the only ones.
Citing Mylan's EpiPen, two senators introduced a bill cracking down on drug misclassifications that cost Medicaid millions in underpaid rebates.
Sticker prices in drug ads might be off the table again, thanks to some in the U.S. House of Representatives.